-
Reckless NY Times reporting fuels disinformation about trans youth
The NY Times’ analysis of this data is so misleading that some advocates question the motives behind the piece: “This is not investigative journalism.”
-
Scientists debate boundaries, ethics of human gene editing
Scientists are arguing about the revolutionary technology, which promises to cure intractable diseases — and threatens to make designer babies a reality.
-
Express Scripts offers low-cost alternative to Turing drug
The nation’s biggest pharmacy benefits manager is muscling back into the debate over soaring drug costs by promoting a cheaper alternative to a life-saving med.
-
Study confirms early treatment is best in combatting HIV
A major international study says don’t delay in seeking HIV treatment: Starting medication soon after diagnosis helps keep people healthy longer.
-
GlaxoSmithKline, UNC form company aimed at finding AIDS cure
The partnership also creates an HIV Cure center bringing together academic and pharmaceutical research scientists.
-
Aetna changes Florida prescription drug policy amid HIV drug complaint
Aetna has agreed to change its prescription drug policy to ensure that Florida consumers with HIV and AIDS can access their medications at lower costs.
-
Study: Stem cell breakthrough opens door to biological children of same-sex couples
An international team of scientists have shown that it is possible to create human sperm and eggs from stem cells derived from adult skin, regardless of the donor’s gender.
-
Study: HIV drug can prevent new infection when taken before and after sex
For the first time, a study shows that a drug used to treat HIV infection also can help prevent it when taken before and after sex between two men.
-
Consumer group sues Aetna, says policy discriminates against HIV patients
The lawsuit alleges a new policy violates the privacy of people with HIV and AIDS by requiring them to get their medications from its mail-order pharmacy.
-
New York regulators tell insurers to cover transgender treatment
Officials say commercial insurers may not deny needed treatment for gender dysphoria when someone’s gender at birth is contrary to his or her identity.